Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.
Wit
Andrew L
AL
College of Physicians & Surgeons of Columbia University, 630 W. 168th Street, New York, NY 10032, USA. alw4@columbia.edu
Duffy
Heather S
HS
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects; D018031:Connexin 43 / Q000378:metabolism; D003326:Coronary Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D015195:Drug Design; D017629:Gap Junctions / Q000187:drug effects* / Q000378:metabolism; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D010766:Phosphorylation; D013997:Time Factors; D020257:Ventricular Remodeling
D000889:Anti-Arrhythmia Agents; D018031:Connexin 43; D009842:Oligopeptides; C477643:rotigaptide